Feasibility of BIBF1120 (nintedanib) combined with low-dose cytarabine in elderly patients with AML ineligible for intensive treatment.

被引：1
|
作者：
Krug, Utz [1 ]
Knoblauch, Nicola [1 ]
Gerss, Joachim [1 ]
Schliemann, Christoph [1 ]
Wiebe, Stefanie [1 ]
Mueller-Tidow, Carsten [1 ]
Berdel, Wolfgang E. [1 ]
机构：
[1] Univ Hosp Muenster, Munster, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期
关键词：
D O I：
10.1200/jco.2014.32.15_suppl.7053
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7053
引用
收藏
页数：1
相关论文
共 50 条
  • [21] PHASE III RANDOMIZED TRIAL OF VOLASERTIB PLUS LOW-DOSE CYTARABINE (LDAC) VERSUS PLACEBO PLUS LDAC IN PATIENTS AGED ≥65 YEARS WITH PREVIOUSLY UNTREATED AML, INELIGIBLE FOR INTENSIVE THERAPY
    Dohner, H.
    Symeonidis, A.
    Sanz, M. A.
    Deeren, D.
    Demeter, J.
    Anagnostopoulos, A.
    Esteve, J.
    Fiedler, W.
    Porkka, K.
    Kim, H. J.
    Lee, J. H.
    Usuki, K.
    Jung, C. W.
    D'Ardia, S.
    Salamero, O.
    Horst, H. A.
    Recher, C.
    Rousselot, P.
    Sandhu, I.
    Theunissen, K.
    Thol, F.
    Dohner, K.
    Teleanu, V.
    DeAngelo, D. J.
    Naoe, T.
    Sekeres, M. A.
    Belsack, V.
    Ge, M.
    Taube, T.
    Ottmann, O. G.
    HAEMATOLOGICA, 2016, 101 : 185 - 186
  • [22] Association of Glasdegib plus Low-Dose Cytarabine (AraC) in the Real-Life Treatment of Very Frail Elderly Acute Myeloid Leukemias (AML) Patients
    Tanasi, Ilaria
    Bruzzese, Antonella
    Di Veroli, Ambra
    Vetro, Calogero
    Rizzo, Lorenzo
    De Luca, Giulia
    Pilo, Federica
    Pravato, Stefano
    Molteni, Alfredo
    Gurrieri, Carmela
    Salutari, Prassede
    Palumbo, Giuseppe Alberto
    Vigna, Ernesto
    Bonifacio, Massimiliano
    Riva, Marta
    Latagliata, Roberto
    BLOOD, 2024, 144 : 6041 - 6042
  • [23] TREATMENT OF ACUTE MYELOID-LEUKEMIA IN THE ELDERLY WITH LOW-DOSE CYTARABINE, HYDROXYUREA, AND CALCITRIOL
    SLAPAK, CA
    DESFORGES, JF
    FOGAREN, T
    MILLER, KB
    AMERICAN JOURNAL OF HEMATOLOGY, 1992, 41 (03) : 178 - 183
  • [24] Phase III randomized trial of volasertib combined with low-dose cytarabine (LDAC) versus placebo plus LDAC in patients aged ≥65 years with previously untreated, acute myeloid leukemia (AML) ineligible for intensive remission induction therapy
    DeAngelo, Daniel J.
    Sekeres, Mikkael A.
    Ottmann, Oliver G.
    Sanz, Miguel A.
    Naoe, Tomoki
    Taube, Tillmann
    Belsack, Valerie
    Ge, Miaomiao
    Doehner, Hartmut
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2015, 15 : S194 - S194
  • [25] Retrospective, real-life study of venetoclax plus azacitidine or low-dose cytarabine in French patients with acute myeloid leukemia ineligible for intensive chemotherapy
    Laloi, Louise
    Billotey, Natacha Chaumard
    Dumas, Pierre-Yves
    Paul, Franciane
    Villate, Alban
    Simand, Celestine
    Fornecker, Luc
    Puisset, Florent
    Bertoli, Sarah
    Simonet, Marion Boissard
    Laribi, Kamel
    Houyou, Dyhia
    Santagostino, Alberto
    Michel, Claire
    Guepin, Gabrielle Roth
    Guerineau, Elodie
    Tabrizi, Reza
    Hunault, Mathilde
    Giltat, Aurelien
    Kaphan, Eleonore
    Bulabois, Claude
    Cartet, Elodie
    Rocher, Clement
    Lachenal, Florence
    Morisset, Stephane
    Recher, Christian
    Pigneux, Arnaud
    Belhabri, Amine
    Michallet, Mauricette
    Michallet, Anne-Sophie
    CANCER MEDICINE, 2023, 12 (06): : 7175 - 7181
  • [26] TREATMENT WITH LOW-DOSE CYTARABINE (LD-ARAC) IN ELDERLY PATIENTS (AGE 70 YEARS OR OLDER) WITH ACUTE MYELOID LEUKEMIA (AML): A SINGLE INSTITUTION EXPERIENCE
    Heiblig, M.
    El Ahmri, M.
    Tigaud, I.
    Plesa, A.
    Barraco, F.
    Labussiere-Wallet, H.
    Ducastelle-Lepretre, S.
    Michallet, M.
    Nicolini, F. E.
    Plesa, C.
    Wafter, E.
    Salles, G.
    Thomas, X.
    HAEMATOLOGICA, 2015, 100 : 382 - 382
  • [27] Single-center experience: comparison of reduced intensive chemotherapy and low-dose cytarabine treatment as remission induction in older age aml cases
    Yikilmaz, A. Senturk
    Akinci, S.
    Bakanay, S.
    Dilek, I.
    LEUKEMIA RESEARCH, 2019, 85 : S41 - S42
  • [28] Aclarubicin, Low-Dose Cytarabine Combined With G-CSF (CAG) Regimen For Patients Previously Treated Or Ineligible For Intensive Chemotherapy With Acute Myeloid Leukemia and Myelodysplastic Syndrom: A Single Center Experience
    Minauchi, Koichiro
    Obara, Masato
    Ara, Takahide
    Shima, Kanako
    Yasumoto, Atsushi
    Nakata, Masanobu
    Ota, Shuichi
    Imai, Kiyotoshi
    Hirano, Teiichi
    Kiyama, Yoshio
    Ogasawara, Masahiro
    Kobayashi, Naoki
    Imamura, Masahiro
    BLOOD, 2013, 122 (21)
  • [29] Continuous drip infusion of low dose cytarabine and etoposide with granulocyte colony-stimulating factor for elderly patients with acute myeloid leukaemia ineligible for intensive chemotherapy
    Kanemura, Nobuhiro
    Tsurumi, Hisashi
    Kasahara, Senji
    Hara, Takeshi
    Yamada, Toshiki
    Sawada, Michio
    Goto, Naoe
    Kitagawa, Jun-ichi
    Shimizu, Masahito
    Oyama, Masami
    Moriwaki, Hisataka
    HEMATOLOGICAL ONCOLOGY, 2008, 26 (01) : 33 - 38
  • [30] Analysis of survival of older patients with frontline AML treated with clofarabine with or without low-dose cytarabine or intermediate-dose cytarabine: A matched cohort comparison
    Faderl, S.
    Kashani, F. Ravandi
    Borthakur, G.
    Kadia, T. M.
    Jabbour, E.
    Garcia-Manero, G.
    Brandt, M.
    Pierce, S.
    Kantarjian, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
12345